Organisation paid for research Program year 2023 Source: CMS Open Payments

Accellacare .

Neither a doctor nor a teaching hospital

Research payments

$15,735

4 payments

Through program year 2023, Accellacare . is reported as receiving $15,735 in research payments, across 4 payments.

By program year

1 row

Year	Kind	Amount	Payments
2023	Research	$15,735	4

Breakdown

Who paid Research payments · program year 2023

Novartis Pharmaceuticals Corporation $15,735 4 payments

Studies the money was for Research payments · program year 2023

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $13,602 2 payments
An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $2,100 1 payment
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (Nash) and Liver Fibrosis $32 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.